As of 17 Sept 2026, Glenmark Pharmaceuticals Ltd share price is ₹2,400.00. The stock opened at ₹2,400.00 and had closed at ₹2,407.75 the previous day. Over the last 52 weeks, the stock has recorded a low of ₹1,794.00 and a high of ₹2,536.85. In terms of performance, Glenmark Pharmaceuticals Ltd share price has increased by 10.12% over the past six months and has increased by 14.11% over the last year.
GLENMARK Stock Price Chart
Glenmark Pharmaceuticals Ltd Overview
About GLENMARK
Glenmark Pharmaceuticals is primarily engaged in the business of development, manufacturing and marketing of pharmaceutical products. The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities a
Glenmark Pharmaceuticals Ltd Historical Performance
GLENMARK Futures & Options
Glenmark Pharmaceuticals Ltd Fundamentals
Glenmark Pharmaceuticals Ltd Financials
| Indicator | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Revenue | 9,212.12 | 9,582.78 | 9,059.14 | 9,206.60 | 8,756.21 |
| EBITDA | 48.57 | 2,421.38 | 7,480.02 | 1,962.84 | 2,733.19 |
| Net Profit | -200.80 | 1,610.35 | 5,167.29 | 1,208.77 | 1,997.79 |
| EPS | -7.12 | 57.07 | 183.13 | 42.84 | 70.80 |
Glenmark Pharmaceuticals Ltd Technical Analysis
| Indicator | Value |
|---|---|
| Support 1 (S1) | 2,335.20 |
| Resistance 1 (R1) | 2,452.45 |
| Pivot Point | 2,379.90 |
Glenmark Pharmaceuticals Ltd Dividend History
| Ex Date | Dividends Date | Record Date | Dividend Type | Dividend Details |
|---|---|---|---|---|
| 31-Aug-2026 | 29-May-2026 | 31-Aug-2026 | Final | ₹2.50 |
| 03-Oct-2025 | 26-Sep-2025 | 03-Oct-2025 | Interim | ₹2.50 |
| 15-Sep-2025 | 23-May-2025 | 15-Sep-2025 | Final | ₹2.50 |
| 13-Sep-2024 | 24-May-2024 | 17-Sep-2024 | Final | ₹2.50 |
| 18-Sep-2023 | 19-May-2023 | 19-Sep-2023 | Final | ₹2.50 |
GLENMARK Key Leadership Details
Last Updated: Mar 2026
| Name | Position |
|---|---|
| Glenn Saldanha | Chairman |
| Cheryl Pinto | Executive Directorector (Corporate) |
| Anurag Mantri | Chief Financial Officer |
Glenmark Pharmaceuticals Ltd Peer Comparison
| Company | Price | M.Cap (Cr) | P/E (TTM) | ROE (TTM) |
|---|---|---|---|---|
| Sun Pharmaceutical Industries LtdSUNPHARMA | ₹1,859.00+0.30% | ₹4,19,727.66 | 38.32 | 13.74% |
| Divis Laboratories LtdDIVISLAB | ₹9,262.50+1.14% | ₹1,67,235.91 | 67.46 | 15.32% |
| Torrent Pharmaceuticals LtdTORNTPHARM | ₹4,820.00+0.16% | ₹1,46,951.32 | 64.68 | 25.49% |
Disclaimer
The information provided on this page is for informational purposes only and should not be construed as investment advice, recommendation, or solicitation to buy or sell any securities or financial pr...
Frequently Asked Questions
- The share price of Glenmark Pharmaceuticals Ltd today is ₹2,400.00 on NSE and ₹2,400.00 on BSE.
- The 52-week high of Glenmark Pharmaceuticals Ltd is ₹2,536.85, while the 52-week low is ₹1,794.00.
- The current market capitalisation of Glenmark Pharmaceuticals Ltd is approximately ₹67,953 crore.
- The P/E (Price-to-Earnings) ratio of Glenmark Pharmaceuticals Ltd is 54.06. The ratio may vary with changes in the share price and earnings.
- The P/B (Price-to-Book) ratio of Glenmark Pharmaceuticals Ltd is 6.01. It compares the company’s market value with its book value and can provide an indication of how the market values the company relative to its net assets.
- To buy Glenmark Pharmaceuticals Ltd shares, you first need to open a demat account before you can place an order. Here's the process:
• Open a demat account online using your PAN, Aadhaar and bank details.
• Add funds to your trading account via UPI or net banking.
• Search for GLENMARK on TradeMobi or the Anand Rathi web platform.
• Place your order
• Track your holdings in the portfolio section. - Over the past 3 years, Glenmark Pharmaceuticals Ltd has delivered a return of approximately 181.28%. This return is based on the change in the share price over the specified period and may differ depending on the measurement date. Past performance does not guarantee future returns.
- The shareholding pattern of Glenmark Pharmaceuticals Ltd comprises different categories of shareholders. As of Jun 2026, the shareholding is approximately 46.65% promoters, 4.13% FIIs, 18.60% DIIs, and 10.60% public shareholders.
Download TradeMobi App
- Real-Time Market Data
- Advanced Trading Tools
- Expert-Backed Research
